MX2024012345A - Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r - Google Patents

Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r

Info

Publication number
MX2024012345A
MX2024012345A MX2024012345A MX2024012345A MX2024012345A MX 2024012345 A MX2024012345 A MX 2024012345A MX 2024012345 A MX2024012345 A MX 2024012345A MX 2024012345 A MX2024012345 A MX 2024012345A MX 2024012345 A MX2024012345 A MX 2024012345A
Authority
MX
Mexico
Prior art keywords
antagonist
administration
compositions
treatment
methods
Prior art date
Application number
MX2024012345A
Other languages
English (en)
Spanish (es)
Inventor
Bolanle Akinlade
Lazar Jennifer Sloane
Yong Lin
Wanling Wong
Ying Liu
Lita Araujo
Danielle Isaman
Kerri Ford
Stefano Fiore
Frédéric Marrache
Chad Nivens
Angeliki Giannelou
Jeffrey Curtis
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of MX2024012345A publication Critical patent/MX2024012345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024012345A 2022-04-06 2024-10-04 Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r MX2024012345A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263327850P 2022-04-06 2022-04-06
US202263350761P 2022-06-09 2022-06-09
US202263389317P 2022-07-14 2022-07-14
US202263424035P 2022-11-09 2022-11-09
US202263424627P 2022-11-11 2022-11-11
US202363445329P 2023-02-14 2023-02-14
US202363445331P 2023-02-14 2023-02-14
US202363447796P 2023-02-23 2023-02-23
PCT/US2023/065361 WO2023196838A1 (en) 2022-04-06 2023-04-05 Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist

Publications (1)

Publication Number Publication Date
MX2024012345A true MX2024012345A (es) 2024-11-08

Family

ID=86424726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012345A MX2024012345A (es) 2022-04-06 2024-10-04 Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r

Country Status (11)

Country Link
US (1) US20230399410A1 (https=)
EP (1) EP4504788A1 (https=)
JP (2) JP7630012B2 (https=)
KR (1) KR20240164816A (https=)
CN (1) CN120569404A (https=)
AU (1) AU2023250653A1 (https=)
CA (1) CA3247400A1 (https=)
IL (1) IL316091A (https=)
MX (1) MX2024012345A (https=)
TW (1) TW202405014A (https=)
WO (1) WO2023196838A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149845A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) * 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2017106312A1 (en) * 2015-12-18 2017-06-22 Drexel University Methods of modulating levels of il-6 and pd-l1
EP3980459A1 (en) * 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Also Published As

Publication number Publication date
IL316091A (en) 2024-12-01
JP2025072440A (ja) 2025-05-09
TW202405014A (zh) 2024-02-01
US20230399410A1 (en) 2023-12-14
WO2023196838A1 (en) 2023-10-12
AU2023250653A1 (en) 2024-11-21
KR20240164816A (ko) 2024-11-20
EP4504788A1 (en) 2025-02-12
JP2024526414A (ja) 2024-07-18
CA3247400A1 (en) 2023-10-12
JP7630012B2 (ja) 2025-02-14
CN120569404A (zh) 2025-08-29

Similar Documents

Publication Publication Date Title
MX2024012345A (es) Composiciones y metodos para el tratamiento de la polimialgia reumatica mediante la administracion de un antagonista del il-6r
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
CL2022002830A1 (es) Anticuerpo anti-ox40 y usos del mismo
MX2022016039A (es) Anticuerpos anti-cd2.
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
CO2021017737A2 (es) Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide
BR112023005399A2 (pt) Anticorpo biespecífico, uso de um anticorpo biespecífico, métodos para tratamento de uma doença em um indivíduo e para prevenir ou mitigar um efeito adverso, inibidor de tirosina quinase, uso de um inibidor de tirosina quinase e invenção
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
MX2024001189A (es) Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
MX2025000365A (es) Dosis para tratamiento con anticuerpos biespecificos anti-fcrh5/anti-cd3
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo
CO2022017828A2 (es) Composiciones y métodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide
MX2024004762A (es) Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
MX2025011114A (es) Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r
BR112022021641A2 (pt) Tratamento de combinação de anticorpos anti-cd40 para câncer
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
MX2024009715A (es) Inmunoconjugado y su uso del mismo.
CL2024003050A1 (es) Método e intermediario para la preparación de apalutamida.
PH12019550203A1 (en) Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour